The global intravenous immunoglobulin (IVIG) market was valued at USD 14.9 billion in 2025 and is expected to reach USD 25.7 billion by 2033, expanding at a 7.0% CAGR from 2026 to 2033. The market is forecast to increase from USD 16.0 billion in 2026. North America accounted for the largest revenue share at 45.9% in 2025, while Asia Pacific is anticipated to register the fastest growth during the forecast period.

Demand for IVIG is being supported by the increasing prevalence of autoimmune disorders, immunodeficiency diseases, and neurological conditions, alongside greater awareness of immune-related diseases and advances in immunotherapy.

What Is Driving IVIG Market Growth?

The growing incidence of primary and acquired immunodeficiency disorders is a major factor supporting demand for intravenous immunoglobulin therapies. IVIG is widely used as an essential treatment for patients with antibody deficiencies and remains particularly important where alternative treatment options are limited.

An aging population is also contributing to market expansion, as older adults are more susceptible to immune-related and chronic diseases. At the same time, increasing awareness and improvements in disease diagnosis are helping identify previously undiagnosed immune deficiencies.

Lifestyle-related health risks are another contributing factor. Diets high in saturated fats, salt, and sugar, excessive alcohol consumption, and insufficient physical activity have been associated with a broader burden of chronic and immune-related disorders, supporting the need for advanced therapeutic interventions.

Primary Immunodeficiency Is Creating Sustained Demand

According to NCBI data, more than 6 million people worldwide were affected by primary immunodeficiencies (PIDs) in 2020, with an estimated 70% to 90% remaining undiagnosed. More than 430 types of PIDs have been identified, resulting from inherited defects affecting components of the immune system.

Patients with PIDs are more vulnerable to infections and may also face higher risks of autoinflammation, autoimmune disorders, allergies, and malignancies. As diagnosis and awareness improve, more patients are likely to receive appropriate immunoglobulin therapy.

Advances in plasma collection, fractionation, and manufacturing technologies are also expected to strengthen the availability of immunoglobulin products and support long-term market development.

Download a free sample report or claim your copy of this full market intelligence report

Key Market Segments

Application:
Immunodeficiency diseases represented the largest application segment, accounting for 19.5% of global revenue in 2025.

Distribution channel:
Hospital pharmacies dominated distribution, representing 57.1% of revenue in 2025, reflecting the clinical requirements associated with IVIG administration and monitoring.

Regional Market Performance

North America was the largest regional market in 2025, capturing 45.9% of global revenue. The U.S. held the largest country-level market share during the same year.

Asia Pacific is expected to record the fastest CAGR from 2026 to 2033. Increasing healthcare expenditure, improving diagnosis of immune disorders, and growing awareness of advanced therapies are expected to support regional expansion.

IVIG Market Size and Forecast

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Treatment Costs Remain a Major Market Constraint

Despite strong demand, the high cost of IVIG treatment can limit patient access and create financial pressure for healthcare systems. IVIG infusions are commonly administered every three to four weeks, potentially requiring 12 to 16 treatments annually depending on the patient's condition.

The estimated IVIG price is USD 73.89 per gram, while total treatment costs can exceed USD 10,000, depending on disease severity and treatment requirements. Immunoglobulin replacement therapy may continue for six months or longer, increasing the overall financial burden.

The ABIM Foundation estimates that annual IgG treatment costs can exceed USD 30,000, highlighting affordability and reimbursement as important considerations for future market development.

Competitive Landscape

Companies profiled in the intravenous immunoglobulin market study include:

• Biotest AG
• Baxter
• Octapharma AG
• LFB
• Grifols SA
• CSL
• China Biologics Products Inc.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Explore our dedicated business services:

Prism AI: Market Intelligence with Cited Research- Ask questions in plain language and get insights drawn from Grand View Research's entire research library, with sources cited. Create your free account today.

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today